In this article, we will look at the 10 Best 52-Week Low Blue Chip Stocks to Buy Right Now.

The S&P 500 has performed exceedingly well over the past two years, powering to all-time highs amid easing inflation and the artificial intelligence boom. Despite the 24% and 14% gains over the past two years, respectively, not every company has had a great time over the same period.

While some stocks are flirting with record highs after blockbuster gains, others have pulled back significantly and are trading close to their 52-week lows. The stocks have pulled back due to a series of headwinds, including concerns about the economic outlook, monetary policy uncertainty, and deteriorating consumer spending power.

Nevertheless, analysts at Goldman Sachs expect the global bull market to continue, helped by an improving earnings outlook and continued economic growth. Markets have also been reacting to the nomination of Kevin Warsh to succeed current chair Jerome Powell.

“Given this macro backdrop, it would be unusual to see a significant equity setback/bear market without a recession, even from elevated valuations,” said Peter Oppenheimer, Goldman Sachs Research’s chief global equity strategist.

Head of the Applied Equity Advisors Team at Morgan Stanley Investment Management, Andrew Slimmon, expects stocks to edge higher in 2026, thanks to the Fed’s supportive monetary policy. The fact that bull markets last five to seven years also supports the thesis, given that we are in the fourth year of the current bull cycle.

Amid the improving investment environment, let’s take a look at some of the Best 52-Week Low Blue Chip Stocks to Buy Right Now that are trading at a great discount after a deep pullback.

Our Methodology

To curate the Best 52-Week Low Blue Chip Stocks to Buy Right Now, we sifted through blue chip ETFs and compiled a list of their holdings. From the list, we identified stocks trading within 0-5% of their 52-week lows and with an upside potential of more than 20%. We also detailed the number of hedge funds holding stakes in them in the third quarter of 2025. Finally, we ranked the stocks in ascending order of the upside potential.

Note: The data is of February 4

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

Best 52-Week Low Blue Chip Stocks to Buy Right Now

10. Crown Castle Inc. (NYSE:CCI)

Share Price: $86.81

52-Week Range: $83.21 – $115.76

Number of Hedge Fund Holders: 56

Stock Upside Potential: 24.40%

Crown Castle Inc. (NYSE:CCI) is one of the best blue-chip stocks with a 52-week low to buy right now. Crown Castle Inc. (NYSE:CCI) released its fourth-quarter 2025 earnings on February 4, highlighting a company in the midst of a major shift as it moves forward with plans to sell off its fiber and small cell businesses. The company’s EPS came in at $0.67, beating the estimates by $0.12, while revenue was $1.07 billion, slightly exceeding expectations. The company is cutting roughly 20% of its workforce as it prepares to sell its fiber business, with the layoffs and other cost-cutting measures expected to save about $65 million annually.

For the full year 2025, Crown Castle surpassed its financial targets across all key metrics. Site rental revenue reached $4.05 billion, adjusted EBITDA totaled $2.86 billion, and adjusted funds from operations (AFFO) came in at $1.90 billion, all exceeding guidance. The year’s results were fueled by 4.9% organic growth, excluding the impact of Sprint churn, demonstrating strong operational performance despite challenges in the industry.

Looking ahead, the company expects pressure in 2026 from DISH terminations and Sprint cancellations, forecasting declines in site rental revenue and adjusted EBITDA. However, AFFO is projected to edge higher on lower interest costs and cost-cutting initiatives. Crown Castle plans to maintain its $4.25 annual dividend, repurchase $1 billion in shares, and reduce debt by $7 billion, with management viewing 2026 as a growth trough and anticipating improved momentum in 2027 and beyond.

Crown Castle Inc. (NYSE:CCI) is a leading real estate investment trust (REIT) and provider of shared communications infrastructure in the U.S., owning and operating over 40,000 cell towers and 85,000+ route miles of fiber. The company enables mobile connectivity by leasing space on these towers and supporting small-cell networks for carriers, including 5G and other technologies.

9. Abbott Laboratories (NYSE:ABT)

Share Price: $109.30

52-Week Range : $105.27- $141.23

Number of Hedge Fund Holders: 68

Stock Upside Potential: 27.21%

Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data through January 7. That figure is up from 736 severe adverse events and seven deaths disclosed in November.

The FDA issued an early alert on December 2 and later classified the matter as a Class I recall on January 14, its most serious category. Abbott had cautioned that defective sensors could produce inaccurate glucose readings, potentially leading patients to delay or skip insulin doses. The company said the problem was traced to a single production line and has since been resolved.

On January 23, UBS reiterated a Buy rating on Abbott Laboratories and set a $158 price target. The bullish stance underlines the research firm’s confidence in the company’s prospects, despite recent concerns about lower-than-expected fourth-quarter results.

There are growing concerns about the company’s 2026 organic sales growth of about 7%, following its 3.8% organic sales growth. UBS said that despite a sales miss, Abbott showed financial resilience, posting earnings of $1.50 per share in line with expectations and guiding to 2026 EPS of $5.55 to $5.80, broadly in line with consensus at the midpoint. UBS expects the company to return to high single-digit organic growth, including the reacceleration of the electrophysiology business in the US.

The company’s revenue base is also expected to benefit from the launch of the Volt Pulsed Field Ablation System. The research firm also expects the stock to receive a boost from the upcoming clinical trial for left atrial appendage closure. It also expects Abbott Laboratories to be one of the primary beneficiaries of continuous glucose monitoring becoming the standard of care in diabetes over the next three years.

Abbott Laboratories (NYSE:ABT) is a global healthcare company that researches, develops, and manufactures medical devices, diagnostic tools, branded generic medicines, and nutritional products.